Аннотация
Появление множественно-резистентных возбудителей заставляет пересматривать отношение к ряду известных и давно используемых препаратов, в частности к полимиксинам – группе полипептидных антибиотиков, продуцируемых Bacillus polymyxa, и высокоактивных в отношении грамотрицательной микрофлоры – Escherichia coli, Klebsiella spp., Enterobacter spp., Salmonella spp., Shigella spp., Haemophilus influenzae, Brucella spp., Pseudomonas aeruginosa, Acinetobacter spp. и др. Все виды Proteus spp., Serratia marcescens, грам(+) бактерии и многие анаэробы, в частности Bacteroides fragilis, нечувствительны к действию полимиксинов. В клинической практике используются полимиксин В и колистин (полимиксин Е), которые в современных условиях могут применяться лишь как препараты «глубокого» резерва при лечении инфекций, вызванных грамотрицательными микроорганизмами с множественной устойчивостью к другим классам антибиотиков. В статье представлен также обзор литературы по опыту клинического применения полимиксинов.
-
1.
Moellering R.C. Antibiotic resistance: Lessons for the future. Clin Infect Dis 1998; 27 (Suppl. 1): 135-40.
-
2.
Drew J. Drug Int J 1993; 22: 1059-64.
-
3.
SCRIP 1995; 27: 2054.
-
4.
Hancock R.E.W., Chapple D.S. Peptide antibiotics. Antimicrob Agents Chemother 1999; 43: 1317-23.
-
5.
O'Grady F., Greenwood D. Cyclic peptides. In: O'Grady F., Lambert H.P., Finch R.G., Greenwood D., editors. Antibiotics and Chemotherapy. 7th ed. New York: Churchill Livingstone; 1997. p. 336-44.
-
6.
Mestres C., Alsina M., Busquets M., et al. Interaction of colistin with lipids in liposomes and monolayers. Int J Pharm 1998; 160: 99-107.
-
7.
Koch-Weser J., Sidel V.W., Federman E.B., et al. Adverse effects of sodium colistimethate. Ann Intern Med 1970; 72: 857.
-
8.
Strutchfield J., Jones P.M., Howell S.L. The effects of polymyxin B, a protein kinase C inhibitor, on insulin secretion from intact and permeabilized islets of Langerhans. Biochem Biophys Res Commun 1986; 136: 1001.
-
9.
Amir S., Sasson S., Kalser N. Polymyxin B is an inhibitor of insulin-induced hypoglycemia in the whole animal model: Studies on the mode of inhibitory action. J Biol Chem 1987; 262: 6663.
-
10.
Henriksen E.J., Sleeper M.D., Zierath J.R., et al. Polymyxin B inhibits stimulation of glucose transport in muscle by hypoxia or contractions. Ann J Physiol 1989; 256: E662.
-
11.
Cavaillon J.M., Haeffner-Cavaillon N. Polymyxin B inhibition of LPS-induced interleukin-1 secretion by human monocytes is dependent upon the LPS origin. Mol Immunol 1986; 23: 965.
-
12.
Stokes D.C., Shenep J.L., Fishman M., et al. Polymyxin B prevents lipopolysaccharide-induced release of tumor necrosis factors from alveolar macrophages. J Infect Dis 1989; 160: 52.
-
13.
Flynn P.M., Shenep J.L., Stokes D.C., et al. Polymyxin moderates acidosis and hypotension in established, experimental gram-negative septicemia. J Infect Dis 1987; 156: 706.
-
14.
Tauber M.G., Shibl A.M., Hackbarth C.J., et al. Antibiotic therapy, endotoxin concentration in cerebrospinal fluid, and brain edema in experimental Escherichia coli meningitis in rabbits. J Infect Dis 1987; 156: 456.
-
15.
Bender B.S., Winchurch R.A., Trupari J.N., et al. Depressed natural killer cell function in terminally injured adults: Successful in vivo and in vitro immunomodulation and the role of endotoxin. Clin Exp Immunol 1988; 71: 120-5.
-
16.
Ingoldby C.J., McPherson G.A., Blamgart L.H. Endotoxemia in human obstructive jaundice: Effect of polymyxin B. Am J Surg 1984; 147: 766.
-
17.
Catchpole C.R., Andrews J.M., Brenwald N., et al. A reassessment of the in vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997; 39: 255-60.
-
18.
Moore R.A.. Hancock R.E. Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob Agents Chemother 1986; 30: 923.
-
19.
Peterson A.A., Fesik S.W., McGroarty E.J. Decreased binding of antibiotics to lipopolysaccharides from polymyxin-resistant strains of Escherichia coli and Salmonella typhimurium. Antimicrob Agents Chemother 1987; 31: 230.
-
20.
Rosenblatt J.E., Stewart P.R. Combined activity of sulfamethoxazole, trimethoprim and polymyxin B against gram-negative bacilli. Antimicrob Agents Chemother 1974; 6: 84.
-
21.
Cornelissen F., Van de Bossche H. Synergism of the antimicrobial agents miconasole, bacitracin and polimixin B. Chemother 1983; 29: 419.
-
22.
Collins M.S., Pappagagiorus D. Inhibition of Coccidiodes immitis in vitro and enhancement of amphotericin B by polymyxin B. Antimicrob Agents Chemother 1975; 7: 419.
-
23.
Hogg G.M., Barr J.G., Webb C.H. In vitro activity of the combination of colistin and rifampicin against milty-drug-resistant strains of A. baumannii. J Antimicrob Chemother 1998; 41: 494-5.
-
24.
Meyers B.R., Gurtman A.C. Polymyxin B. Colistin. In: Gorbach S.L., Bartlett J.G., Blacklow N.R., editors. Infect Dis; 1998: p. 2594.
-
25.
Fekety J., Norman P.S., Cluff L.E. The treatment of gram-negative bacillary infections with colistin. Ann Intern Med 1962; 57: 214.
-
26.
Murdock J. The treatment of severe Pseudomonas pyocyanea infections with colistin. Proceedings of the Third International Congress of Chemotherapy; 1964; Stuttgart, Germany. p. 319.
-
27.
Moore M.B., McCulley J.P. Acanthamobea keratitis associated with contact lenses: Six consecutive cases of successful management. Br J Ophthalmol 1989; 73: 271.
-
28.
Ledingham I.M., Alcock S.R., Eastaway A.T., et al. Triple regimen of selective decontamination of the digestive tract, systemic cefotaxime, and microbiological surveillance for prevention of acquired infections in intensive care. Lancet 1988; 1: 785.
-
29.
Johanson W.G., Siedenfeld J., et al. Prevention of nosocomial pneumonia using topical and parenteral antimicrobial agents. Am Rev Respir Dis 1988; 137: 265.
-
30.
Levin A.S., Bazone A.A., Penco J., et al. Intravenous colistin as therapy for nosocomial infections caused by multydrug-resistant P. aeruginosa and A. baumannii. Clin Infect Dis 1999; 28: 1008-11.
-
31.
Feeley T., DuMoulin G., Hedley-Whyte J., et al. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med 1975; 193: 471.
-
32.
Unertl K., Ruckdeschel G., Selbmann H., et al. Prevention of colonization and respiratory infections in long-term ventilated patients by local antimicrobial prophylaxis. Intens Care Med 1987; 13: 106.
-
33.
Conway S.P., Pond H.N., Watson A., et al. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1996; 52: 987-93.
-
34.
Zylberberg H., Vargaftig J., Barbieux C., et al. Prolonged efficiency of secondary prophylaxis colistin aerosols for respiratory infection due to P. aeruginosa in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 641-3.
-
35.
Kurrle E., DeKiler A., Gaus W., et al. Prevention of infection in acute leukemia: A prospective randomized study of two different drug regimes for antimicrobial prophylaxis. Infections 1986: 14: 226.
-
36.
Manan F., Kibbler C., Noone P. Activity of ciprofloxacin and colistin against Pseudomonas aeruginosa isolates from neutropenic patients: A possible approach to prophylaxis (letter). J Antimicrob Chemother 1988; 22: 953.
-
37.
Frederiksen B., Koch C., Noiby N. Antibiotic treatment of initial colonization with P. aeruginosa postpones chronic infections and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmon 1997; 23: 330-5.
-
38.
Bauldoff G.S., Nunley D.R., Manzetti J., et al. Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantating. Transplantation 1997; 64: 748-52.
-
39.
Klugman K.P., Dagan R. Efficacy and safety of meropenem in the treatment of meningitis. Antimicrob Agents Chemother 1995; 39: 1140-6.
-
40.
Jimenez-Mejias M.E., Pachon J., Becerril B., et al. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis 1997; 24: 932-5.
-
41.
Urban C., Go E., Mariano N., et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993; 167: 448-51.
-
42.
Wood C.A., Reboli A.C. Infections causes by imipenem-resistant A. calcoaceticus biotype anitratus. J Infect Dis 1993; 168: 1602-3.
-
43.
Corbella X., Pujol M., Ayats J., et al. Relevance of digestive tract colonization in the epidemiology of multiresistant Acinetobacter baumannii. Clin Infect Dis 1996; 23: 329-34.
-
44.
Go E.S., Urban C., Burns J., et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994; 344: 1329-32.
-
45.
Bergogne-Berezin E., Towner K.J. Acinetobacter spp. as nosocomial pathogens: microbiological. Clinical and epidemiological features. Clin Microbiol Rev 1996; 9: 148-65.
-
46.
Fernandes-Viladrich P., Corbella X., Corral L., et al. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethat sodium. Clin Infect Dis 1999; 28: 916-7.